Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 21668632)

1.

Can the dropout risk of candidates with hepatocellular carcinoma predict survival after liver transplantation?

Cucchetti A, Cescon M, Bertuzzo V, Bigonzi E, Ercolani G, Morelli MC, Ravaioli M, Pinna AD.

Am J Transplant. 2011 Aug;11(8):1696-704. doi: 10.1111/j.1600-6143.2011.03570.x. Epub 2011 Jun 10.

2.

Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.

Ioannou GN, Perkins JD, Carithers RL Jr.

Gastroenterology. 2008 May;134(5):1342-51. doi: 10.1053/j.gastro.2008.02.013. Epub 2008 Feb 13.

PMID:
18471511
3.

Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy.

Huo TI, Huang YH, Su CW, Lin HC, Chiang JH, Chiou YY, Huo SC, Lee PC, Lee SD.

Clin Transplant. 2008 Jul-Aug;22(4):469-75. doi: 10.1111/j.1399-0012.2008.00811.x. Epub 2008 Mar 3.

PMID:
18318736
4.

Liver transplantation for hepatocellular carcinoma: the MELD impact.

Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH.

Liver Transpl. 2004 Jan;10(1):36-41.

5.

Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma.

Wong SN, Reddy KR, Keeffe EB, Han SH, Gaglio PJ, Perrillo RP, Tran TT, Pruett TL, Lok AS.

Liver Transpl. 2007 Mar;13(3):334-42.

6.

Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.

Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM.

Dig Dis Sci. 2012 Mar;57(3):806-12. doi: 10.1007/s10620-011-1910-9. Epub 2011 Sep 28.

7.

Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Washburn K, Edwards E, Harper A, Freeman R.

Am J Transplant. 2010 Jul;10(7):1643-8. doi: 10.1111/j.1600-6143.2010.03127.x. Epub 2010 May 10.

8.

A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.

Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, Morel P, Mentha G, Combescure C.

Hepatology. 2012 Jul;56(1):149-56. doi: 10.1002/hep.25603. Epub 2012 Jun 18.

PMID:
22271250
9.

A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.

Piscaglia F, Camaggi V, Ravaioli M, Grazi GL, Zanello M, Leoni S, Ballardini G, Cavrini G, Pinna AD, Bolondi L.

Liver Transpl. 2007 Jun;13(6):857-66.

10.

Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.

Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box T.

Liver Transpl. 2012 Apr;18(4):423-33. doi: 10.1002/lt.23385.

11.

Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft.

Yi NJ, Suh KS, Lee HW, Shin WY, Kim J, Kim W, Kim YJ, Yoon JH, Lee HS, Lee KU.

Liver Transpl. 2009 May;15(5):496-503. doi: 10.1002/lt.21606.

12.

Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States.

Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, Roberts J, Reich DJ, Schwartz ME, Mieles L, Lee FT, Florman S, Yao F, Harper A, Edwards E, Freeman R, Lake J.

Liver Transpl. 2010 Mar;16(3):262-78. doi: 10.1002/lt.21999.

13.

Liver transplantation for patients with hepatocellular carcinoma at the Liver Cancer Institute of Fudan University, China.

Zhou J, Fan J, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Wang Z, Sun J, Xiao YS, He YF, Yang GH, Song K, Yuan Z, Wang YQ, Tang ZY.

Chin Med J (Engl). 2005 Apr 20;118(8):654-9.

PMID:
15899120
14.

Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation.

Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V.

Am J Transplant. 2006 Aug;6(8):1957-62. Epub 2006 Jun 9.

15.

Liver transplantation in the MELD era: a single-center experience.

Sachdev M, Hernandez JL, Sharma P, Douglas DD, Byrne T, Harrison ME, Mulligan D, Moss A, Reddy K, Vargas HE, Rakela J, Balan V.

Dig Dis Sci. 2006 Jun;51(6):1070-8.

PMID:
16865573
16.

Waiting list removal rates among patients with chronic and malignant liver diseases.

Freeman RB, Edwards EB, Harper AM.

Am J Transplant. 2006 Jun;6(6):1416-21.

17.
18.

Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?

Moya A, Berenguer M, Aguilera V, Juan FS, Nicolás D, Pastor M, López-Andujar R, Rayón M, Orbis F, Mora J, De Juan M, Carrasco D, Vila JJ, Prieto M, Berenguer J, Mir J.

Liver Transpl. 2002 Nov;8(11):1020-7.

19.

Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score.

Zhao WH, Ma ZM, Zhou XR, Feng YZ, Fang BS.

World J Gastroenterol. 2002 Apr;8(2):237-42.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk